The University of Chicago Header Logo

Connection

David T. Rubin to Cohort Studies

Back to Details
This is a "connection" page, showing publications David T. Rubin has written about Cohort Studies.
David T. Rubin
Connection Strength
0.742
Cohort Studies
  1. Dose escalation of biologics in biologic-naive patients with Crohn's disease: Outcomes from the ODESSA-CD study. J Manag Care Spec Pharm. 2024 Nov; 30(11):1276-1287.
    View in: PubMed
    Score: 0.150
  2. Cumulative Histologic Inflammation Predicts Colorectal Neoplasia in Ulcerative Colitis: A Validation Study. Inflamm Bowel Dis. 2021 01 19; 27(2):203-206.
    View in: PubMed
    Score: 0.115
  3. Effects of non-medical switching on outcomes among patients prescribed tumor necrosis factor inhibitors. Curr Med Res Opin. 2017 11; 33(11):1945-1953.
    View in: PubMed
    Score: 0.092
  4. The impact of ulcerative colitis on patients' lives compared to other chronic diseases: a patient survey. Dig Dis Sci. 2010 Apr; 55(4):1044-52.
    View in: PubMed
    Score: 0.052
  5. Association of colorectal cancer and prostate cancer and impact of radiation therapy. Cancer Epidemiol Biomarkers Prev. 2009 Jul; 18(7):1979-85.
    View in: PubMed
    Score: 0.052
  6. Association between colorectal cancer and urologic cancers. Arch Intern Med. 2008 May 12; 168(9):1003-9.
    View in: PubMed
    Score: 0.048
  7. What is the most effective way to communicate results after endoscopy? Gastrointest Endosc. 2007 Jul; 66(1):108-12.
    View in: PubMed
    Score: 0.045
  8. Vedolizumab and Anti-Tumour Necrosis Factor a Real-World Outcomes in Biologic-Naïve Inflammatory Bowel Disease Patients: Results from the EVOLVE Study. J Crohns Colitis. 2021 Oct 07; 15(10):1694-1706.
    View in: PubMed
    Score: 0.030
  9. Effective Treatment of Acute Severe Ulcerative Colitis in Pregnancy Is Associated With Good Maternal and Fetal Outcomes. Clin Gastroenterol Hepatol. 2021 11; 19(11):2444-2446.e2.
    View in: PubMed
    Score: 0.028
  10. Long-term safety of vedolizumab for inflammatory bowel disease. Aliment Pharmacol Ther. 2020 10; 52(8):1353-1365.
    View in: PubMed
    Score: 0.028
  11. Risk factors and treatment outcomes of peristomal pyoderma gangrenosum in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2020 06; 51(12):1365-1372.
    View in: PubMed
    Score: 0.027
  12. Risk of Postoperative Complications Among Inflammatory Bowel Disease Patients Treated Preoperatively With Vedolizumab. Am J Gastroenterol. 2017 Sep; 112(9):1423-1429.
    View in: PubMed
    Score: 0.023
  13. Pharmacogenomics-Based Point-of-Care Clinical Decision Support Significantly Alters Drug Prescribing. Clin Pharmacol Ther. 2017 Nov; 102(5):859-869.
    View in: PubMed
    Score: 0.022
  14. Subdural hemorrhage in pediatric patients with enlargement of the subarachnoid spaces. J Neurosurg Pediatr. 2013 Apr; 11(4):438-44.
    View in: PubMed
    Score: 0.017
  15. Claudin-1 and claudin-2 expression is elevated in inflammatory bowel disease and may contribute to early neoplastic transformation. Lab Invest. 2008 Oct; 88(10):1110-20.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.